Skip to content

Chun Yang

21 papers in the library · 2,097 citations · publishing 2015-2025

Papers

Sort Most recent Most cited

Microglial BDNF modulates arketamine's antidepressant-like effects through cortico-accumbal pathways.

Science Advances July 11, 2025 Lujuan He, Xuenan Wang, Shilin Luo et al. 8 citations

Arketamine, the (R)-enantiomer of (R,S)-ketamine, shows even greater rapid and sustained antidepressant-like effects in rodent models compared to esketamine, yet the underlying mechanisms remain unclear. In this study, we used the chronic social defeat stress (CSDS) model to investigate how arketamine exerts its antidepressant-like effects. We found that activating cAMP response element-binding...

S-ketamine alleviates morphine-induced hyperalgesia via decreasing the gut Enterobacteriaceae levels: Comparison with R-ketamine.

Neuroscience March 5, 2025 Hanyu Liu, Siqi Yang, Qi Zhang et al.

Opioid-induced hyperalgesia (OIH) is a serious complication during the pain treatment. Ketamine has been commonly reported to treat OIH, but the mechanisms remain unclear. Gut microbiota is recently recognized as one of the important mechanisms underlying the occurrence and treatment of OIH. However, whether ketamine enantiomers could alleviate OIH through gut microbiota that still needs to be...

Myelin Repair as a Novel Mechanism for Ketamine's Sustained Antidepressant Effects.

Current Neuropharmacology January 16, 2025 Sen Wang, Chaoli Huang, Mengyu Wang et al. 4 citations

Depression is a prevalent mental disorder, affecting approximately 300 million people worldwide. Despite decades of research into the underlying mechanisms of depression, a consensus remains elusive. Recent studies have implicated changes in oligodendrocytes and myelin in the pathogenesis of depression. Conventional antidepressants may alleviate symptoms within weeks of use, but approximately...

A bibliometric analysis of research on psychedelics for depression treatment.

Heliyon September 15, 2024 Hao Hua, Xinghuo Fu, Wenli Wang et al. 2 citations

Psychedelics, as a class of potent psychoactive substances, significantly alter sensory perception and mood, thereby profoundly impacting cognition. Increasing evidence indicates that psychedelics can facilitate individual social function and rapidly and sustainably improve symptoms of moderate and severe depression. The growing interest in psychedelics as potential treatments for depression...

The role of CD38 in inflammation-induced depression-like behavior and the antidepressant effect of (R)-ketamine.

Brain, behavior, and immunity October 1, 2023 Xinying Zhang, Teng He, Zifeng Wu et al.

CD38 is involved in immune responses, cell proliferation, and has been identified in the brain, where it is implicated in inflammation processes and psychiatric disorders. We hypothesized that dysfunctional CD38 activity in the brain may contribute to the pathogenesis of depression. To investigate the underlying mechanisms, we used a lipopolysaccharide (LPS)-induced depression model and...

Depression and antidepressant effects of ketamine and its metabolites: The pivotal role of gut microbiota.

Neuropharmacology September 1, 2022 Hao-Ming Hua, Chao Huang, Hanyu Liu et al. 35 citations

The discovery of the robust antidepressant actions of ketamine is regarded as one of the greatest advancements in depression treatment in the past 60 years. Recent findings have provided strong evidence for the presence of bidirectional communication networks between the gastrointestinal tract and the brain in depression. Moreover, increasing evidence supports the antidepressant role of...

Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine

Molecular Psychiatry November 24, 2021 W. Yao, Qianqian Cao, Shilin Luo et al. 208 citations

(R,S)-ketamine elicits rapid-acting and sustained antidepressant actions in treatment-resistant patients with depression. (R)-ketamine produces longer-lasting antidepressant effects than (S)-ketamine in rodents; however, the precise molecular mechanisms underlying antidepressant actions of (R)-ketamine remain unknown. Using isobaric Tag for Relative and Absolute Quantification, we identified...

miR-98-5p plays a critical role in depression and antidepressant effect of ketamine

Translational Psychiatry September 3, 2021 Chao Huang, Yuanyuan Wang, Zifeng Wu et al. 29 citations

Ketamine has been demonstrated to be a rapid-onset and long-lasting antidepressant, but its underlying molecular mechanisms remain unclear. Recent studies have emerged microRNAs as important modulators for depression treatment. In this study, we report that miR-98-5p is downregulated in the prefrontal cortex and hippocampus of mice subjected to chronic social stress, while overexpressing it by...

Ketamine Alleviates Postoperative Depression-Like Symptoms in Susceptible Mice: The Role of BDNF-TrkB Signaling

Frontiers in Pharmacology February 6, 2020 Shan Li, Xiaoxiao Luo, Dongyu Hua et al.

Patients are more likely to suffer from central nervous system (CNS) complications after anesthesia and surgery. However, postoperative depression (POD) has not yet received sufficient attentions, and its pathogenesis and therapeutic strategies remain poorly understood. We here aimed to investigate whether brain derived neurotrophic factor (BDNF)-tropomyosin-related kinase B (TrkB) signaling...

Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1

Translational Psychiatry January 27, 2020 Kai Zhang, Chun Yang, Lijia Chang et al. 120 citations

In rodent models of depression, (R)-ketamine has greater potency and longer-lasting antidepressant effects than (S)-ketamine; however, the precise molecular mechanisms underlying the antidepressant actions of (R)-ketamine remain unknown. Using RNA-sequencing analysis, we identified novel molecular targets that contribute to the different antidepressant effects of the two enantiomers. Either...

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites

Translational Psychiatry November 7, 2019 Chun Yang, Jianjun Yang, A. Luo et al. 189 citations

Although the robust antidepressant effects of the N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown. NMDAR inhibition and the subsequent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation are...

Role of Actinobacteria and Coriobacteriia in the antidepressant effects of ketamine in an inflammation model of depression

Pharmacology, Biochemistry and Behavior 2019 Nian-nian Huang, Dongyu Hua, Gaofeng Zhan et al.

ABSTRACT Ketamine, an N‐methyl‐d‐aspartic acid receptor (NMDAR) antagonist, elicits rapid‐acting and sustained antidepressant effects in treatment‐resistant depressed patients. Accumulating evidence suggests that gut microbiota via the gut‐brain axis play a role in the pathogenesis of depression, thereby contributing to the antidepressant actions of certain compounds. Here we investigated the...

Is (S)-norketamine an alternative antidepressant for esketamine?

European Archives of Psychiatry and Clinical Neuroscience July 14, 2018 Kenji Hashimoto, Chun Yang

The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)ketamine has been hailed as the most important advance in the treatment of depression for the past 50 years. The rapid and sustained antidepressant effects of (R,S)-ketamine have spurred a great deal of research interest, with growing off-label use for the treatment of depression, although the concerns about the safety of repeated...

Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model.

Biological Psychiatry 2018 Chun Yang, Q. Ren, Y. Qu et al. 249 citations

BACKGROUND The role of the mechanistic target of rapamycin (mTOR) signaling in the antidepressant effects of ketamine is controversial. In addition to mTOR, extracellular signal-regulated kinase (ERK) is a key signaling molecule in prominent pathways that regulate protein synthesis. (R)-Ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine. Here we...

Possible role of the gut microbiota–brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model

Translational Psychiatry December 15, 2017 Chun Yang, Youge Qu, Yuko Fujita et al. 231 citations

Accumulating evidence suggests that the gut microbiota-brain axis plays a role in the pathogenesis of depression, thereby contributing to the antidepressant actions of certain compounds. (R)-ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine. Here, we investigated whether the gut microbiota plays a role in the antidepressant effects of these two ketamine...

Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model

Scientific Reports November 10, 2017 Youge Qu, Chun Yang, Qian Ren et al. 126 citations

Accumulating evidence suggests a key role of the gut-microbiota-brain axis in the antidepressant actions of certain compounds. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, showed rapid and sustained antidepressant effects in treatment-resistant depressed patients. In contrast, another NMDAR antagonist, lanicemine, did not exhibit antidepressant effects in such patients....

Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine

The International Journal of Neuropsychopharmacology October 7, 2016 Chao Dong, Ji-Chun Zhang, Wei Yao et al. 116 citations

Background: Similar to the N-methyl-D-aspartate receptor antagonist ketamine, the metabotropic glutamate 2/3 receptor antagonist, MGS0039, shows antidepressant effects. However, there are no reports comparing these 2 compounds in the social defeat stress model of depression. Methods: We examined the effects of MGS0039 (1 mg/kg) and ketamine (10 mg/kg) on depression-like behavior in susceptible...

Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression

Psychopharmacology August 3, 2016 Bangkun Yang, Ji-Chun Zhang, Mei Han et al. 93 citations

RATIONALE: The N-methyl-D-aspartate (NMDA) receptor antagonists, including R-ketamine and rapastinel (formerly GLYX-13), show rapid antidepressant effects in animal models of depression. OBJECTIVE: We compared the rapid and sustained antidepressant effects of R-ketamine and rapastinel in the social defeat stress model. RESULTS: In the tail suspension and forced swimming tests, R-ketamine (10...

Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model

Translational Psychiatry February 23, 2016 H-L Sun, Z-Q Zhou, G.-F. Zhang et al. 87 citations

Although ketamine shows a rapid and sustained antidepressant effect, the precise mechanisms underlying its effect are unknown. Recent studies indicate a key role of p11 (also known as S100A10) in depression-like behavior in rodents. The present study aimed to investigate the role of p11 in the antidepressant-like action of ketamine in chronic unpredictable mild stress (CUMS) rat model. The...

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

Translational Psychiatry September 1, 2015 Chun Yang, Yukihiko Shirayama, J-C Zhang et al. 600 citations

Although the efficacy of racemate ketamine, a rapid onset and sustained antidepressant, for patients with treatment-resistant depression was a serendipitous finding, clinical use of ketamine is limited, due to psychotomimetic side effects and abuse liability. Behavioral and side-effect evaluation tests were applied to compare the two stereoisomers of ketamine. To elucidate their potential...

Combination of Nitrous Oxide with Isoflurane or Scopolamine for Treatment-resistant Major Depression

Clinical Psychopharmacology and Neuroscience April 1, 2015 Chun Yang, Kenji Hashimoto

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Combination of Nitrous Oxide with Isoflurane or Scopolamine for Treatment-resistant Major...